State of Wyoming Trims Position in Charles River Laboratories International, Inc. $CRL

State of Wyoming decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 61.1% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,403 shares of the medical research company’s stock after selling 2,203 shares during the quarter. State of Wyoming’s holdings in Charles River Laboratories International were worth $242,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. First Trust Advisors LP lifted its position in Charles River Laboratories International by 44.5% during the first quarter. First Trust Advisors LP now owns 8,736 shares of the medical research company’s stock worth $1,507,000 after buying an additional 2,689 shares during the period. Madison Asset Management LLC increased its stake in shares of Charles River Laboratories International by 7.2% during the 1st quarter. Madison Asset Management LLC now owns 16,752 shares of the medical research company’s stock valued at $2,890,000 after acquiring an additional 1,130 shares during the last quarter. Van Berkom & Associates Inc. increased its stake in shares of Charles River Laboratories International by 11.2% during the 1st quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock valued at $86,449,000 after acquiring an additional 50,462 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Charles River Laboratories International during the 1st quarter worth about $331,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after acquiring an additional 210,260 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the sale, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $235.61 on Thursday. The firm’s fifty day simple moving average is $203.64 and its 200 day simple moving average is $187.73. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $242.73. The firm has a market capitalization of $11.35 billion, a price-to-earnings ratio of -62.66, a PEG ratio of 2.68 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Monday, April 13th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research note on Monday, July 20th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Finally, Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a research report on Friday, May 8th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus target price of $220.75.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.